Further examples abound in other tumor types, such as the association of ERBB2 [16] and CRKL [17] amplification with resistance to anti-epidermal growth factor receptor (EGFR) targeted agents in non small-cell lung cancer and YAP amplification with resistance to doxorubicin in hepatocellular carcinoma [18]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.